ADMdx’s CEO, Dawn Matthews, will be an invited panel speaker at the Alzheimer’s Drug Discovery Foundation (ADDF)’s upcoming Therapeutic Investigator Day on October 23, 2023. This symposium will be held in conjunction with the Clinical Trials for Alzheimer’s Disease (CTAD) conference in Boston, MA. Ms. Matthews’ talk will focus on the role of biomarkers in […]
The National Institutes of Aging (NIA) has approved the second year of funds for ADMdx’s $2 million Small Business Innovation Research grant. This work focuses on the development of a diagnostic product to detect the effects of Traumatic Brain Injury due to repetitive head impact and differentiate them from dementias such as Alzheimer’s disease. ADMdx […]
Dawn Matthews gave an invited presentation at the Society for Nuclear Medicine and Molecular Imaging (SNMMI), describing the Amyloid PET Profile developed by the Quantitative Imaging Biomarkers Alliance Amyloid PET working group. This Profile identifies sources of technical variability that can reduce the statistical power of measuring changes in amyloid in the brain. It provides […]
ADMdx is co-lead author with Cerveau Technologies on a newly published paper describing the results of a visual read method for the tau PET tracer MK-6240 manufactured by Cerveau. Tau is one of two abnormal proteins that are the basis for a diagnosis of Alzheimer’s disease, and the ability to measure it using a brain […]
The Radiological Society of North America (RSNA) Quantitative Imaging Biomarkers Alliance (QIBA) has established a working group to develop a Profile for the radiology and clinical trial community regarding the quantitative measurement of tau PET imaging. Tau, one of the two hallmark abnormal proteins in Alzheimer’s disease, can now be imaged in the living brain […]
Guidelines established by the Quantitative Imaging Biomarkers Alliance (QIBA) Amyloid PET working group, co-chaired by Dawn Matthews of ADMdx and Anne Smith of Siemens Healthineers, have been published. The article in Journal of Neuroscience summarizes the multi-year work of the group, which defined criteria for PET image acquisition and measurement to reduce variability in results. […]
ADM Diagnostics, Inc. (ADMdx) has been awarded a two-year $1.96 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Aging (NIA) to develop a diagnostic test to detect the effects of repeated head impact upon the brain, and to differentiate these effects from Alzheimer's disease. Repeated sub-concussive impact to the […]
ADMdx has been awarded a new patent pertaining to a machine learning approach to differentiate brain effect patterns associated with multiple different diseases within the same brain scan. Patients often have more than one disease or syndrome that can cause cognitive impairment, such as the development of Alzheimer’s disease in a majority of adults with […]
Led by editors Dr. Jeffrey Cummings, Dr. Jeffrey Kinney and Dr. Howard Fillit, the book Alzheimer's Disease Drug Development: Research and Development Ecosystem has been published. Dawn Matthews, ADMdx CEO, was selected to be the primary author of the chapter on neuroimaging in Alzheimer’s Disease clinical trials. This book provides a comprehensive overview of the […]
In collaboration with Dr. Ana Pereira of Mount Sinai Medical Center and Rockefeller University, ADMdx studied the effects of the drug Riluzole upon brain metabolism and cognition in patients with Alzheimer’s Disease. In this study led by Dr. Pereira, Principal Investigator, FDG PET imaging was used to measure regional brain metabolism (which reflects neuronal function) before […]